First-episode psychosis Mental and Behavioural Disorders First-episode psychosis
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Diagnosis of a psychotic disorder by a clinician, which can include affective psychosis or non-affective psychoses 2. Receiving specialized services for first-episode psychosis 3. Considered symptomatically stable,as judged by their primary clinicians 4. Capable of interacting on the online platform and participating in focus groups and semi-structured interviews, as judged by their primary clinicians 5. 18 years of age or older 6. Low or at most moderate suicidal risk for the month preceding study entry 7. Able to nominate an emergency contact to be eligible for the study
Exclusion criteria
Exclusion criteria: 1. Intellectual disability 2. Hospitalization at the time of recruitment 3. Inability to speak or read English 4. Individuals diagnosed with antisocial personality disorder and/or borderline personality disorder 5. Individuals in the acute phase of mania or psychosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Acceptability (perceived ease of use and perceived usefulness), assessed by the following: 1. Horyzons-Canada Acceptability, Usability, Safety, and Impact Questionnaire (HC-AUSI-Q), a questionnaire and semi-structured interview that includes questions on perceived ease of use, perceived usefulness, enjoyment, and safety. This will be assessed at the baseline (initial interview and orientation meeting) and at the 8 week follow-up (Horyzons exit interview) 2. Website usage analytics, in terms of frequency, duration and patterns of use over the study duration | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Safety, assessed using: 1.1. Specific questions in the HC-AUSI-Q examining users views and experience on Horyzons-Canada. In addition, any incidents and adverse events in relation to use of the online system will be carefully monitored and quantified. This will be assessed at the 8 week follow-up. 1.2. Semi-structured interviews (assessed at the 8 week follow-up) and focus group discussion (qualitative data) (assessed at 4 week follow-up). 2. Social functioning, measured at the baseline and 8 week follow-up using the following: 2.1. Social and Occupational Functioning Assessment Scale (SOFAS) 2.2. Personal and Social Performance Scale (PSP) 3. Global improvement and therapeutic response, assessed using the Clinical Global Impression ( CGI) at the baseline and 8 week follow-up 4. The following will be assessed at baseline and 8 week follow-up: 4.1. Positive and negative symptoms, depression, anxiety, stress, suicidal ideations, assessed using the Brief Psychiatric Rating Scale (BPRS) 4.2. Positive symptoms, assessed using the Scale for the Assessment of Positive Symptoms (SAPS) 4.3. Social support, assessed using the Multidimensional Scale of Perceived Social Support (MSPSS) 4.4. Negative symptoms, assessed using the Scale for the Assessment of negative symptoms (SANS) 4.5. Self-esteem, assessed using the Self-Esteem Rating Scale (SES) 4.6. Strengths, assessed using the Strengths Use Scale (SUS) 4.7. Depression, assessed using the Calgary Depression Scale (CDS) 5. Access and use of technology, assessed using the Access and Use of Technology Questionnaire at the baseline 6. Impact of the intervention, assessed qualitatively through focus group discussion at the 4 week follow-up and through semi-structured interviews at the 8 week follow-up | — |
Countries
Canada